España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Dianthus Therapeutics
DNTH
NASDAQ
Watchlist
Get Report
Perks
Buy
Compare Brokers
$29.20
0.2
0.69%
Pre-Market: 4:18 PM EDT
15 minutes delayed
Get Report
Watch
Dianthus Therapeutics (DNTH) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Dianthus Therapeutics (NASDAQ:DNTH) Stock
Dianthus Therapeutics Stock (NASDAQ: DNTH)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, June 28, 2024
Dianthus Therapeutics Announces Two Poster Pr...
Benzinga Newsdesk
Thursday, June 27, 2024
Dianthus Therapeutics shares are trading high...
Benzinga Newsdesk
Cantor Fitzgerald Initiates Coverage On Diant...
Benzinga Newsdesk
Wednesday, June 12, 2024
Dianthus Therapeutics shares are trading high...
Benzinga Newsdesk
Dianthus Therapeutics Bags FDA Permit to Init...
Benzinga Newsdesk
Thursday, May 16, 2024
HC Wainwright & Co. Initiates Coverage On Dia...
Benzinga Newsdesk
Friday, May 10, 2024
What 5 Analyst Ratings Have To Say About Dianthus Therapeutics
Benzinga Insights
Wedbush Maintains Outperform on Dianthus Ther...
Benzinga Newsdesk
Thursday, May 09, 2024
Dianthus Therapeutics Q1 EPS $(0.54) Misses $...
Benzinga Newsdesk
Thursday, April 18, 2024
What 5 Analyst Ratings Have To Say About Dianthus Therapeutics
Benzinga Insights
Raymond James Maintains Outperform on Dianthu...
Benzinga Newsdesk
Friday, March 22, 2024
Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Avi Kapoor
Dianthus Therapeutics shares are trading high...
Benzinga Newsdesk
Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday
Avi Kapoor
Wedbush Maintains Outperform on Dianthus Ther...
Benzinga Newsdesk
Thursday, March 21, 2024
Dianthus Therapeutics Q4 EPS $(0.71) Beats $(1.01) Estimate, Sales $457.00K Beat $310.00K Estimate
Happy Mohamed
Monday, February 26, 2024
Dianthus Therapeutics Has Initiated Phase 2 M...
Benzinga Newsdesk
Thursday, February 15, 2024
Decoding 4 Analyst Evaluations For Dianthus Therapeutics
Benzinga Insights
Stifel Initiates Coverage On Dianthus Therape...
Benzinga Newsdesk
Wednesday, January 31, 2024
Avidity Partners Management LP Reported 9.9% ...
Benzinga Newsdesk
Friday, January 26, 2024
Wedbush Maintains Outperform on Dianthus Ther...
Benzinga Newsdesk
Monday, January 22, 2024
Why Dianthus Therapeutics (DNTH) Stock Is Exploding Higher
Henry Khederian
Dianthus Therapeutics shares are trading high...
Benzinga Newsdesk
Dianthus Therapeutics Enters Agreement For Pr...
Benzinga Newsdesk
Tuesday, December 26, 2023
Jefferies Initiates Coverage On Dianthus Ther...
Benzinga Newsdesk
Wednesday, November 22, 2023
Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst
Vandana Singh
Wedbush Initiates Coverage On Dianthus Therap...
Benzinga Newsdesk
Thursday, November 09, 2023
Dianthus Therapeutics Q3 EPS $(3.78), Sales $...
Benzinga Newsdesk
Friday, September 29, 2023
394K Reasons To Be Bullish On Dianthus Therapeutics Stock
Benzinga Insights
Thursday, September 28, 2023
Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst
Vandana Singh
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023
Benzinga Insights
Raymond James Initiates Coverage On Dianthus ...
Benzinga Newsdesk
Friday, September 22, 2023
Dianthus Therapeutics Insider Trades Send a Signal
Benzinga Insights
Thursday, September 14, 2023
Director at Dianthus Therapeutics, Inc. - Common Stock Acquires Company Stock Options Worth 6,500 Shares
Benzinga Insights
Dianthus Therapeutics, Inc. - Common Stock Director Awarded $85K Worth of Stock Options
Benzinga Insights
Board Member at Dianthus Therapeutics, Inc. - Common Stock Acquires Company Stock Options Worth 6,500 Shares
Benzinga Insights
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch